Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label,...

Keywords

MedicinePaclitaxelPembrolizumabGastroesophageal JunctionCancerOpen labelEsophagogastric junctionInternal medicineGastroenterologyRandomized controlled trialSurgeryAdenocarcinomaImmunotherapy

Affiliated Institutions

Related Publications

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median ov...

2021 The Lancet 2580 citations

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima , Manish A. Shah , Kei Muro +24 more

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...

2020 Journal of Clinical Oncology 1110 citations

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

David Cunningham , Naureen Starling , Sheela Rao +7 more

Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer. (Current Controlled Tria...

2008 New England Journal of Medicine 2285 citations

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

Charles S. Fuchs , Toshihiko Doi , Raymond Woo-Jun Jang +26 more

IMPORTANCE Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. OBJECTIVE To evaluate the safe...

2018 JAMA Oncology 1757 citations

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran , Nils Homann , Claudia Pauligk +54 more

Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-ba...

2019 The Lancet 2355 citations

Publication Info

Year: 2018
Type: article
Volume: 392
Issue: 10142
Pages: 123-133
Citations: 1262
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1262

OpenAlex

Cite This

APA Style

                            
                                
                                    Kohei Shitara, 
                                
                                    Mustafa Özgüroğlu, 
                                
                                    Yung‐Jue Bang
                                
                                et al.
                            
                            (2018). 
                            Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. 
                            The Lancet
                            , 392
                            (10142)
                            , 123-133.
                            https://doi.org/10.1016/s0140-6736(18)31257-1
                        

Identifiers

DOI: 10.1016/s0140-6736(18)31257-1